“Currently, the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) are recommended for U.S. children, and the recommendations vary by age group and risk group. Use of PCV15 as an alternative to PCV13 is expected to further reduce pneumococcal disease incidence in children and adolescents. PCV15 as an option for pneumococcal conjugate vaccination is expected to reduce pneumococcal disease incidence in children because it induces immunity against additional disease-causing serotypes. Findings from RCTs suggested that the immunogenicity and safety of PCV15 are generally comparable to those of PCV13. Cost-effectiveness studies demonstrated that routine use of PCV15 for children aged <2 years was cost-saving, assuming that the cost and effectiveness of PCV15 for the 13 shared serotypes will remain comparable to those of PCV13 and that PCV15 will provide protection against the two additional serotypes.”
HER3 AS AN ADC TARGET: FROM OVERLOOKED RECEPTOR TO ONCOLOGY’S NEXT FRONTIER
In this week’s ADC Spotlight, Suhail Ahmed Kabeer Rasheed takes HER3 from “undruggable” to centre stage as one
